CA3180535A1 - Therapeutic use of pleuromutilins - Google Patents
Therapeutic use of pleuromutilinsInfo
- Publication number
- CA3180535A1 CA3180535A1 CA3180535A CA3180535A CA3180535A1 CA 3180535 A1 CA3180535 A1 CA 3180535A1 CA 3180535 A CA3180535 A CA 3180535A CA 3180535 A CA3180535 A CA 3180535A CA 3180535 A1 CA3180535 A1 CA 3180535A1
- Authority
- CA
- Canada
- Prior art keywords
- hydroxy
- mutilin
- compound
- diastereomer
- lefamulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
- C07C321/16—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011474P | 2020-04-17 | 2020-04-17 | |
| EP20170072.1 | 2020-04-17 | ||
| US63/011,474 | 2020-04-17 | ||
| EP20170072 | 2020-04-17 | ||
| EP20183292.0 | 2020-06-30 | ||
| EP20183292 | 2020-06-30 | ||
| PCT/EP2021/025140 WO2021209174A1 (en) | 2020-04-17 | 2021-04-16 | Therapeutic use of pleuromutilins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3180535A1 true CA3180535A1 (en) | 2021-10-21 |
Family
ID=75801547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3180535A Pending CA3180535A1 (en) | 2020-04-17 | 2021-04-16 | Therapeutic use of pleuromutilins |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230174472A1 (https=) |
| EP (1) | EP4135682A1 (https=) |
| JP (2) | JP2023522644A (https=) |
| CN (1) | CN115443131A (https=) |
| BR (1) | BR112022020007A2 (https=) |
| CA (1) | CA3180535A1 (https=) |
| IL (1) | IL297268A (https=) |
| TW (1) | TW202203908A (https=) |
| WO (1) | WO2021209174A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250134844A1 (en) | 2022-02-09 | 2025-05-01 | Nabriva Therapeutics GmbH | Therapeutic use of pleuromutilins |
| EP4338732A1 (en) | 2022-09-16 | 2024-03-20 | Nabriva Therapeutics GMBH | Lefamulin and its derivatives for use in the treatment of tularemia |
| CN119925362A (zh) * | 2023-11-03 | 2025-05-06 | 阳光安津(南京)生物医药科技有限公司 | 一种化合物在制备用于治疗银屑病的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298733B1 (en) * | 2005-06-27 | 2016-05-25 | Nabriva Therapeutics AG | Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group |
| EP1972618A1 (en) | 2007-03-20 | 2008-09-24 | Nabriva Therapeutics AG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
| GB0803707D0 (en) | 2008-02-28 | 2008-04-09 | Cambridge Entpr Ltd | Antiviral agent |
| EP2399904A1 (en) * | 2010-05-26 | 2011-12-28 | Nabriva Therapeutics AG | Process for the preparation of pleuromutilins |
| CN103204787B (zh) | 2012-01-17 | 2014-10-01 | 北京艾百诺科技有限公司 | 含有取代方酸的乙酸妙林酯及其应用 |
| CN103242210B (zh) | 2012-02-09 | 2014-09-24 | 北京艾百诺科技有限公司 | 含有取代方酸的乙酸妙林酯及其应用 |
| KR102656841B1 (ko) | 2015-06-17 | 2024-04-12 | 나브리바 테라퓨틱스 게엠베하 | 레파뮬린의 주사가능한 약제학적 제형 |
| CN110507823B (zh) * | 2019-08-20 | 2021-08-24 | 中国医学科学院基础医学研究所 | 衣康酸相关物质在诊断、防治病毒感染性疾病中的应用 |
-
2021
- 2021-04-16 CN CN202180028994.6A patent/CN115443131A/zh active Pending
- 2021-04-16 IL IL297268A patent/IL297268A/en unknown
- 2021-04-16 TW TW110113773A patent/TW202203908A/zh unknown
- 2021-04-16 US US17/919,200 patent/US20230174472A1/en active Pending
- 2021-04-16 BR BR112022020007A patent/BR112022020007A2/pt not_active Application Discontinuation
- 2021-04-16 JP JP2022562465A patent/JP2023522644A/ja active Pending
- 2021-04-16 EP EP21723641.3A patent/EP4135682A1/en active Pending
- 2021-04-16 WO PCT/EP2021/025140 patent/WO2021209174A1/en not_active Ceased
- 2021-04-16 CA CA3180535A patent/CA3180535A1/en active Pending
-
2025
- 2025-12-04 JP JP2025230606A patent/JP2026041886A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023522644A (ja) | 2023-05-31 |
| IL297268A (en) | 2022-12-01 |
| BR112022020007A2 (pt) | 2022-11-22 |
| WO2021209174A1 (en) | 2021-10-21 |
| EP4135682A1 (en) | 2023-02-22 |
| TW202203908A (zh) | 2022-02-01 |
| US20230174472A1 (en) | 2023-06-08 |
| CN115443131A (zh) | 2022-12-06 |
| JP2026041886A (ja) | 2026-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026041886A (ja) | プレウロムチリンの治療的使用 | |
| US5290540A (en) | Method for treating infectious respiratory diseases | |
| EP4135683B1 (en) | Antiviral use of pleuromutilins | |
| KR20150013527A (ko) | 항염증 활성과 접합된 증진된 항인플루엔자제 | |
| CN115836079B (zh) | 烟酰胺单核苷酸和烟酰胺核苷衍生物及其在治疗特别是由流感病毒或冠状病毒引起的病毒感染和呼吸道并发症中的用途 | |
| JP6594853B2 (ja) | チオ糖粘液溶解薬 | |
| EP3556377A1 (en) | Antiviral immunotropic agent for the treatment of acute respiratory viral infections | |
| KR20200101428A (ko) | 최적화된 화합물 | |
| WO2020241759A1 (ja) | インフルエンザウイルス感染症またはコロナウイルス感染症の予防および/または治療剤 | |
| CN118742310B (zh) | 一种次黄碱衍化合物在制备治疗肺纤维化药物中的应用 | |
| US20070099855A1 (en) | Glycyrrhizin or derivatives thereof for for treating or preventing severe acute respiratory syndrome (sars) | |
| CN115484953A (zh) | 治疗细胞因子风暴综合症及相关疾病的方法 | |
| JP2023524081A (ja) | ヒアルロナンコンジュゲートの使用 | |
| EP4135681B1 (en) | Antiviral use of pleuromutilins | |
| MX2012005551A (es) | Tratamiento de infecciones microbianas. | |
| EP4125924B1 (en) | Furosemide compositions for use in supportive therapy in coronavirus infection | |
| JPH05310578A (ja) | ミゾリビンを有効成分とする感染疾患の予防または治療剤 | |
| WO2025257401A1 (en) | Novel isophthalate compounds for the treatment of a viral lung infection | |
| WO2025257398A1 (en) | Dicarboxylic acids and esters thereof for use in the treatment of a viral lung infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241028 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250324 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250410 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250410 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250410 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250410 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250410 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250411 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250520 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250520 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250520 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250521 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250521 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250808 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260224 |